Kraig Biocraft Laboratories Announces Plans to Launch Initial Commercial Production of Monster Silk(TM)
May 07 2013 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the
leading developer of advanced spider silk based fibers, today
announced plans to launch its initial commercial production of
Monster Silk™. The announcement of the Company's decision to launch
commercial production follows the early successes of its of Monster
Silk™ pilot production program.
"We have received strong indications of interest from potential
customers and potential commercialization partners," said, CEO and
founder, Kim Thompson. "Many of these companies have been very
patient with the fact that our laboratory production has been
limited and can not satisfy their demand for quantities of material
sufficient to run test weaves and end product testing.
"Moving from our pilot production program to commercial
production is a very big jump, but it is also a natural
progression," continued Thompson. "We have been laying
the groundwork for this expansion over the last twelve
months. We are confident in the decision and we are hopeful
that we can accomplish the launch during the third and fourth
quarters. Our plan is to begin commercial production to meet
customer needs, secure future orders and capture market share in
the technical textiles market."
Kraig's pilot production program will continue to run, in order
to supply continuing data and help grow the Company's production
capacity.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully
reporting biotechnology company is the leading developer of
genetically engineered spider silk based fiber technologies. The
Company has achieved a series of scientific breakthroughs in the
area of spider silk technology with implications for the global
textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "if," "develops," "researching,"
"research," "pilot," "potential," "could" or other words or phrases
of similar import. Forward looking statements include descriptions
of the Company's business strategy, outlook, objectives, plans,
intentions and goals. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024